Prostate cancer is the most common cancer and second leading cause of death in men.
The evidence base for the diagnosis and treatment of prostate cancer is continually changing. We aim to review and discuss past and contemporary papers on these topics to provoke debate and highlight key dilemmas faced by the urological community. We review key papers on prostate-specific antigen screening, radical prostatectomy versus surveillance strategies, targeted therapies, timing of radiotherapy and alternative anti-androgen therapeutics. Previously, the majority of patients, irrespective of risk, underwent radical open surgical procedures associated with considerable morbidity and mortality. Evidence is emerging that not all prostate cancers are alike and that low-grade disease can be safely managed by surveillance strategies and localized treatment to the prostate. The question remains as to how to accurately stage the disease and ultimately choose which treatment pathway to follow.
Rodney S, Shah TT, Patel HR, Arya M. Are you the author?
Division of Surgery and Interventional Science, University College London, London, UK.
Reference: Expert Rev Anticancer Ther. 2014 Nov;14(11):1379-84.